RESEARCHER PROFILE
Dr Mark Adams, Senior Research Fellow
School of Biomedical Sciences & Centre for Genomics and Personalised Health
Queensland University of Technology (QUT)
Dr. Mark Adams is a researcher at Queensland University of Technology, working within the School of Biomedical Sciences and Faculty of Health, as well as the Centre of Genomics and Personalised Health. He has been with the university for the past decade, and his main research focus is on lung cancers. Dr. Adams completed his undergraduate studies at the Queensland University of Technology and then went on to earn his PhD based at the Mater Research Institute at the Mater hospital. His PhD focused on prostate cancer and specifically looked at developing drugs that would stop the metastasis of prostate cancer towards the bone.
After completing his PhD, Dr. Adams returned to Queensland University of Technology to commence a postdoctoral fellowship. During his fellowship, he looked at lung cancer and how our genomes are maintained through a process called DNA repair. Dr. Adams has been successful in attracting funding to support his salary through fellowship support from foundations such as Cure Cancer, National Health and Medical Research Council, and the Queensland government.
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
Dr. Adams’ research is driven by his fascination with trying to understand how something works and, in particular, understanding cells and the molecular mechanisms underpinning how those cells work. He has always been interested in biology and was drawn to the problem of cancer and what’s going on in those tumour cells that promote tumorigenesis.
Dr. Adams has a young family with three kids, all in primary school. He enjoys downhill mountain biking in the forest and playing futsal on Monday nights.
-
Understanding the experience of pain for novel brain-based treatments
Associate Professor Tasha Stanton leads the Persistent Pain Research Group at SAHMRI. She is also co-Director of IIMPACT in Health at the University of South Australia, Adelaide. She is a clinical pain neuroscientist, with original training as a physiotherapist, and her research focusses on pain – why do we have it and why doesn’t it go away?
-
Relationship between language-literacy skills and mental health
In an innovative move towards enhancing mental health services, Associate Professor Amanda Neil and team, supported by the RHH Research Foundation, are undertaking a crucial study on language-literacy skills of patients within mental health care settings. This year-long project, which commenced in April 2024, seeks to unravel to what extent, where and for whom language-literacy skills are being considered in Tasmanian mental health service provision.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
